First case series on the use of imiquimod for morphoea

Summary Background  Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)‐β. Objective  Our objective was to use imiquimod 5% cream (Aldara™), an inducer of interferon‐γ, known to inhibit TGF‐β, to treat morphoea. Methods  Patients with morphoea were treated with imiquimod and evaluated during their follow‐up visits to 6 months. Results  The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness. Conclusion  This is the first case series describing the successful application of imiquimod in the management of morphoea.